Zetta Genomics, which specialises in using genomic data to power precision medicine, has closed a new seed round, raising £1.8 million (around 2.1 million euros). In total, the UK company has raised £6.2 million (around 7.25 million euros) in three seed rounds since 2022.

In this case, the funding was acquired during an extension of its second seed round, in which it had raised £1.9 million. The company aims to expand its global operations and customer offerings to transform precision medicine and personalised healthcare.

Initial approach
In October 2022, Zetta Genomics opened its first international office in Valencia, with a team that, as it announced at the time, “will play an important role in optimising the engineering of XetaBase, our highly automated and genetically optimised data management platform”. Now, the company is continuing to prioritise Spain in its international growth, which will also have an initial focus on the United Kingdom and the United States.

As part of its roadmap, Zetta Genomics also plans to achieve 500,000 genomes under management, set up new capabilities, deepen bioinformatics and translation expertise and develop engineering capabilities to ensure a continuous cycle of innovation, development and delivery. Later this year, it will also launch a new round of Series A financing.

Faster and more accurate diagnostics
The company's founder and CEO, Ignacio Medina, said, “Zetta Genomics is already making a difference for patients, as XetaBase enables physicians to make faster and more accurate diagnoses at scale. With this extension of our second round of seed funding now completed, we are expanding and innovating our technologies and improving our customer focus.”

Louise Warme, Head of We Venture Capital, one of the new investors, explained, “Zetta provides an incredibly powerful tool for data analysis and management in the rapidly expanding NGS (next generation sequencing) market. Increased speed and accuracy in analysis will support both patient outcomes and workflows for the healthcare system and research.”

Genomic potential
Among the repeat investors, Marc Subirats, General Partner at Nina Capital, commented, “Genomics-based predictive and precision medicine has the potential to deliver uniquely targeted research, therapies and care, driving radical improvements both in terms of health outcomes and health economics. Zetta Genomics' genomics data management and analysis technologies are ideally positioned to harness genomic potential.”

In the past year, the Cambridge-based UK company has forged strategic partnerships with major companies such as Microsoft, Fujitsu and IQVIA. Cambridge University Investment Director, Elaine Loukes, who also participated in this round, said, “Zetta Genomics' pioneering technologies (which emerged from the University of Cambridge) are maturing to the point where they will make medical research more efficient and provide increasingly effective and affordable care. Zetta Genomics' technologies will drive better health outcomes for millions of people around the world.”

^{Photo: Zetta Genomics}